BioTNS to Lead $19.5M South Korean Government Program for Ultra-Precision Digital PCR Standards
核心洞察
BioTNS (搜索) has been selected to spearhead a 30 billion won ($19.53 million) South Korean government initiative to establish technical standards for ultra-precision digital PCR diagnostics.
The seven-year program brings together 15 institutions, including six companies, two state-backed research institutes, and seven university hospitals, to build critical infrastructure for precision medicine.
BioTNS (搜索) will leverage its LQ Suite all-in-one dPCR platform to develop diagnostic and monitoring kits for minimal residual disease (搜索) across multiple cancer types, including gastric, liver, colorectal, and breast cancers.
South Korea has launched an ambitious national effort to set global technical standards for ultra-precision digital Polymerase Chain Reaction (dPCR) diagnostics, naming molecular diagnostics company BioTNS (搜索) as the lead organization. The 30 billion won ($19.53 million) multi-ministerial program, announced Friday, represents a seven-year commitment to establishing the country as a leader in next-generation molecular diagnostics.
The consortium assembled for this initiative spans 15 institutions, including six companies, two state-backed research institutes, and seven university hospitals. Alongside BioTNS (搜索), participating companies include Gencurix (搜索), Hanil Scientific (搜索), JNP Medi (搜索), and Omicsyn (搜索), while GC Labs (搜索) will support clinical validation and commercialization efforts. The National NanoFab Center and the Korea Research Institute of Bioscience and Biotechnology will provide technology support, and seven hospitals — including Catholic University Seoul St. Mary's Hospital, Severance Hospital, and Asan Medical Center — will conduct clinical trials and efficacy evaluations.
Overcoming Limitations of Legacy Molecular Testing
The government program is designed to address the core limitations of legacy molecular testing methods and build critical infrastructure for ultra-precision medicine based on domestic technologies. By establishing technical standards for dPCR, South Korea aims to secure global leadership in a field increasingly central to personalized therapeutic decision-making.
At the heart of the initiative is BioTNS (搜索)'s LQ Suite dPCR system, an all-in-one integrated platform that automates the entire diagnostic workflow — from initial sample preparation to final results. The company intends to use the program to optimize and advance this platform toward becoming a global diagnostic standard.
Pipeline Expansion Across Oncology and Beyond
BioTNS (搜索) plans to develop diagnostic and monitoring kits for minimal residual disease (搜索) (MRD) in hematologic malignancies (搜索) and solid tumors, including gastric, liver, colorectal, and breast cancers. The company is also expanding its pipeline into brain tumors (搜索), neurodegenerative diseases (搜索), and cardiovascular conditions (搜索), signaling a broad ambition beyond oncology.
"Securing the role of lead enterprise for this major multi-ministerial project is a monumental milestone that validates the distinct and unparalleled technological prowess of BioTNS (搜索) on a national level," said BioTNS Co-CEO Kim Bong-suk.
A National Push for Precision Medicine
The initiative reflects South Korea's strategic investment in domestic diagnostic capabilities, with the goal of delivering ultra-precise medical services through independently developed technology. "By elevating our independently developed dPCR platform into the world's finest diagnostic standard, we are fully committed to delivering unprecedented, ultra-precise medical services to patients and healthcare professionals alike in this new era of precision medicine," Kim added.
The seven-year timeline underscores the long-term nature of the undertaking, with clinical trials and efficacy evaluations conducted across the consortium's hospital network forming a critical component of the validation pathway.